| Literature DB >> 35295831 |
Stephanie Alice Treichl1, Wing Mann Ho1, Ruth Steiger2,3, Astrid Ellen Grams2, Andreas Rietzler2,3, Markus Luger4, Elke Ruth Gizewski2,3, Claudius Thomé1, Ondra Petr1.
Abstract
Background: Acute changes of cerebral energy metabolism in early brain injury (EBI) after aneurysmal subarachnoid hemorrhage (aSAH) may play a crucial role for overall neurological outcome. However, direct detection of these alterations is limited. Phosphorous magnetic resonance spectroscopy (31P-MRS) is a molecular-based advanced neuroimaging technique allowing measurements of pathophysiological processes and tissue metabolism based on various phosphorous compound metabolites. This method may provide objective assessment of both primary and secondary changes. Objective: The aim of this pilot study was to evaluate the feasibility and the diagnostic potential of early 31P-MRS in aSAH.Entities:
Keywords: 31-P-MR-spectroscopy; brain metabolism; early brain injury; energy status; subarachnoid hemorrhage
Year: 2022 PMID: 35295831 PMCID: PMC8919991 DOI: 10.3389/fneur.2022.831537
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Demographic data of all included patients.
| 13 patients | Male | 2 | |
| Female | 11 | ||
| Age (years) | 54.5 | Range | 34–70 |
| H&H class | 1 | 7 | |
| 2 | 2 | ||
| 3 | 3 | ||
| 4 | 1 | ||
| 5 | 0 | ||
| Treatment | Surgical | 9 | |
| Endovascular | 4 | ||
| Localization | ACOM | 5 | |
| ACI | 1 | ||
| MCA | 2 | ||
| PCOM | 3 | ||
| DACA (pericallosal artery) | 2 | ||
| EVD/monitoring | None | 6 | |
| EVD/monitoring | 7 |
ACOM, anterior communicating artery; ACI, internal carotid artery; MCA, middle cerebral artery; PCOM, posterior communicating artery; DACA, distal anterior cerebral artery or pericallosal artery; EVD, external ventricular drain.
Figure 1Spectroscopy with voxel.
ANOVA, ratios of phosphorous metabolites.
|
|
|
|
|
|---|---|---|---|
| PCr/ATP | 1.1238 (1.1780–1.2698) | 1.1098 (1.0824–1.1371) | |
| PCr/Pi | 4.5417 (4.2975–4.7859) | 3.7722 (3.6305–3.9140) | |
| Pi/ATP | 0.3273 (0.3096–0.3450) | 0.3531 (0.3424–0.3638) | |
| PME/PDE | 0.8099 (0.7557–0.8640) | 0.9377 (0.8867–0.9886) |
PCr, Phosphocreatine; Pi, inorganic phosphate; ATP, adenosine triphosphate; PME, phosphomonoester; PDE, phosphodiester.
Figure 2PCr/ATP ratio, PCR/Pi ratio, Pi/ATP ratio, and PME/PDE ratio in SAH patients and control group. ANOVA performed.
Figure 3PCr/ATP ratio in patients treated microsurgically and endovascularly compared to healthy control group.
Figure 4PCr/ATP ratio analyzed according to initial clinical presentation compared to healthy control group.
ANOVA, analysis regarding initial clinical presentation, treatment modality, analgosedation, and ventilation and inserted EVD and monitoring.
|
|
|
|
| |
|---|---|---|---|---|
| Cerebrovascular territories | ||||
| Treatment modality | n.s | n.s | n.s | n.s |
| Analgosedation and mechanical ventilation | ||||
| EVD and monitoring | n.s | n.s | n.s | n.s |
| Initial clinical presentation |
PCr, Phosphocreatine; Pi, inorganic phosphate; ATP, adenosine triphosphate; PME, phosphomonoester; PDE, phosphodiester; EVD, external ventricular drain.